DJIA 17,778.92 95.34 0.54%
NASDAQ 4,997.46 5.52 0.11%
S&P 500 2,081.34 12.58 0.61%
market minute promo


company name or ticker

Consolidation Is Good - Cramer's Mad Money (5/18/15)

Biotech Stock Roundup: Alexion to Buy Synageva, FDA Panel Backs Vertex's Orkambi - Analyst Blog

Short Sellers Start to Get Nervous on Biotech

ETFs in Focus on Impressive Q1 Biotech Earnings - ETF News And Commentary

ETFs in Focus on Impressive Q1 Biotech Earnings - ETF News And Commentary

Oppenheimer Downgrades Dyax

Yellen Sounds A Warning, Nasdaq Falls But Biotech Hangs On

Investors Just Doubled Their Money on This Stock

Alexion is paying $8.4 billion to buy Synageva, a company without any sales, so in today's episode we're digging into this deal to see what it may mean to biotech investors.

Will Suitors Line Up to Buy These Biotech Stocks Next?

BioMarin Therapeutic Inc. and Amicus Therapeutics, Inc. are working on ultra-rare disease drugs that could attract an acquirer.

Alexion Acquiring Synageva For $8.4 Billion

Alexion Pharmaceuticals, Inc. (ALXN) in Focus: Stock Jumps 5.1% - Tale of the Tape

See More Articles...